Loading clinical trials...
Loading clinical trials...
A First-in-Human (FIH) Phase 1/2 Study to Assess Safety, Tolerability, and Preliminary Anti-Tumor Activity of REGN7945, an Anti-CD38 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Linvoseltamab, an Anti-BCMA x Anti-CD3 Bispecific Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma
Conditions
Interventions
Linvoseltamab
REGN7945+Linvoseltamab
Locations
7
Australia
Illawarra Cancer Care Centre
Wollongong, New South Wales, Australia
Pindara Private Hospital
Benowa, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Alfred Hospital
Melbourne, Victoria, Australia
St Vincents Hospital Melbourne
Melbourne, Victoria, Australia
University College London Hospitals
London, United Kingdom
Start Date
December 11, 2024
Primary Completion Date
November 11, 2033
Completion Date
November 1, 2035
Last Updated
April 13, 2026
NCT06285318
NCT07523555
NCT07497165
NCT04973605
NCT05862012
NCT07284758
Lead Sponsor
Regeneron Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions